loading...| Preferred Name | Cabazitaxel | |
| Synonyms |
|
|
| Definitions |
A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB). |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C66937 |
|
| Accepted_Therapeutic_Use_For |
metastatic hormone-refractory prostate cancer |
|
| ALT_DEFINITION |
A drug used with prednisone to treat hormone-resistant prostate cancer that has spread and that had been treated with docetaxel. It is also being studied in the treatment of other types of cancer. Cabazitaxel blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. |
|
| CAS_Registry |
183133-96-2 |
|
| CHEBI_ID |
CHEBI:63584 |
|
| Chemical_Formula |
C45H57NO14 |
|
| code |
C66937 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB). |
|
| Display_Name |
Cabazitaxel |
|
| FDA_UNII_Code |
51F690397J |
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Cabazitaxel |
|
| Legacy Concept Name |
XRP6258 |
|
| Maps_To |
Cabazitaxel |
|
| NCI_Drug_Dictionary_ID |
534131 |
|
| PDQ_Closed_Trial_Search_ID |
534131 |
|
| PDQ_Open_Trial_Search_ID |
534131 |
|
| Preferred_Name |
Cabazitaxel |
|
| prefixIRI |
NCIT:C66937 |
|
| prefLabel |
Cabazitaxel |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C2830183 |
|
| subClassOf |